# Histamine H2 Antagonism as Adjuvant Therapy in Treatment Resistant Schizophrenia

> **NCT00565175** · PHASE4 · COMPLETED · sponsor: **Jesper Ekelund** · enrollment: 30 (actual)

## Conditions studied

- Schizophrenia

## Interventions

- **DRUG:** famotidine
- **DRUG:** Placebo (Microcrystallized cellulose)

## Key facts

- **NCT ID:** NCT00565175
- **Lead sponsor:** Jesper Ekelund
- **Sponsor class:** OTHER
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2008-01
- **Primary completion:** 2011-12
- **Final completion:** 2011-12
- **Target enrollment:** 30 (ACTUAL)
- **Last updated:** 2012-03-20

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00565175

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00565175, "Histamine H2 Antagonism as Adjuvant Therapy in Treatment Resistant Schizophrenia". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT00565175. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*